NVAX vs. BCRX, PROK, PRME, ALLO, VALN, HLVX, CABA, EXAI, FATE, and ALEC
Should you be buying Novavax stock or one of its competitors? The main competitors of Novavax include BioCryst Pharmaceuticals (BCRX), ProKidney (PROK), Prime Medicine (PRME), Allogene Therapeutics (ALLO), Valneva (VALN), HilleVax (HLVX), Cabaletta Bio (CABA), Exscientia (EXAI), Fate Therapeutics (FATE), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Novavax (NASDAQ:NVAX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
Novavax received 367 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 74.29% of users gave Novavax an outperform vote while only 66.29% of users gave BioCryst Pharmaceuticals an outperform vote.
Novavax has a net margin of -55.41% compared to BioCryst Pharmaceuticals' net margin of -68.36%.
Novavax currently has a consensus target price of $17.00, indicating a potential upside of 286.36%. BioCryst Pharmaceuticals has a consensus target price of $13.83, indicating a potential upside of 227.03%. Given Novavax's higher probable upside, research analysts plainly believe Novavax is more favorable than BioCryst Pharmaceuticals.
In the previous week, Novavax had 2 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 6 mentions for Novavax and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.38 beat Novavax's score of 0.21 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
53.0% of Novavax shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 0.9% of Novavax shares are owned by insiders. Comparatively, 4.4% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
BioCryst Pharmaceuticals has lower revenue, but higher earnings than Novavax. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Novavax has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
Summary
Novavax and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Novavax News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
